Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average "Moderate Buy" rating from sixteen research firms, with an average 12-month price target of $11.77. Despite this bullish sentiment from analysts, the company's shares are trading down 0.4% at $2.25, and it reported a quarterly loss of $0.13 per share, missing consensus estimates. Institutional investors hold a significant 68.43% of CMPX shares, with several firms recently increasing their positions.
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6
Stifel has reiterated its Buy rating on Compass Therapeutics (CMPX.US) and maintained its target price of $6. This indicates the firm's continued confidence in the company's prospects.
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
This article highlights three promising penny stocks for investors' watchlists: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite varying financial statuses—from pre-revenue to strong growth—all three companies are presented with an overview of their operations, market capitalization, and key financial health indicators, emphasizing their potential for growth in a positive market trend.
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
This article highlights three promising "penny stocks" with strong financial health: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite their status as penny stocks, the companies demonstrate potential for growth and value backed by solid fundamentals. The analysis details their financial performance, market capitalization, and future prospects based on recent earnings and analyst forecasts.
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate
This article assesses Compass Therapeutics' cash burn rate, concluding that despite a high burn rate relative to its market cap, the company has a substantial cash reserve that should last for over two years. The analysis suggests that while the burn rate is a factor, the current cash runway provides a significant buffer against immediate financial concerns.
Compass Therapeutics (CMPX) Short Interest & Short Float | Updated Aug 2026
As of July 31, 2026, Compass Therapeutics (CMPX) had a short interest of 39.87 million shares, representing 27.23% of its public float, marking a 1.47% increase from the prior report. The short interest ratio is 17.6 days to cover, indicating a significant amount of time short sellers would need to cover their positions. The article provides detailed historical short interest data for CMPX and explains key short interest metrics and how they compare to competitors.
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate
Compass Therapeutics (NASDAQ:CMPX) is not causing concern despite its cash burn rate. The company has a cash runway of 3.4 years, and analysts predict it will reach cash flow breakeven before exhausting its funds. Although cash burn increased by 18% last year, its market capitalization is sufficient to raise additional capital if needed without significant shareholder dilution.
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen has downgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy." The company reported a quarterly loss of $0.13 per share, missing analyst expectations, and its shares opened near their 52-week low. Institutional investors hold a significant stake, with several hedge funds recently increasing their positions in the immuno-oncology company.
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS
Compass Therapeutics (NASDAQ:CMPX) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite the earnings miss, the stock rose to $2.15 in Friday trading, though it remains significantly below its 12-month high. Analysts maintain a "Moderate Buy" rating with an average price target of $11.77, and institutional investors hold a substantial portion of the company's shares.
Compass Therapeutics Inc. (CMPX) Stock News Today
This article provides current stock news for Compass Therapeutics Inc. (CMPX), including its recent stock performance, market capitalization, and a note about upcoming earnings. As of the close on August 7th, CMPX stock was up 8.04% at $2.150. The content highlights the company's financial data, ownership, and technical forecasts available on the TradingKey platform.
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com
The article reports on a Form 8K filing by Compass Therapeutics, Inc. for August 6th. The publication, from Investing.com, indicates the filing is publicly available for review. This brief announcement is situated within a broader financial news platform.
Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside
Compass Therapeutics, Inc. (CMPX) has seen its average 12-month stock price target raised to $8.67 from $8.50 by 12 analysts, with forecasts ranging from $4 to $24 per share. This new target suggests a potential upside of approximately 359% based on the Aug. 5 closing price. The consensus rating for CMPX remains a "Buy" from 15 analysts.
Compass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary
Compass Therapeutics, Inc. reported its 2026 quarterly results, showing increased comprehensive and net losses compared to the previous year, driven by advancements in multiple clinical programs and expanded pre-commercialization spending. Despite the losses, the company highlighted positive clinical milestones, pipeline progress with four advancing clinical candidates, and increased operational scale-up. Management anticipates existing cash resources will fund operations into 2028, with plans for future financing through equity, debt, or partnerships.
Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains
Compass Therapeutics (
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its second-quarter 2026 financial results, highlighting a cash position of $180 million expected to fund operations into 2028. The company is advancing several clinical-stage oncology programs, with key updates including anticipated FDA feedback on tovecimig data, ongoing enrollment for CTX-8371 and CTX-10726 cohort expansions, and the planned initiation of a Phase 2 study for CTX-471. The net loss for the quarter was $25.2 million, driven by increased R&D and G&A expenses.
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its second quarter 2026 financial results and provided a corporate update, highlighting ongoing clinical trials for its antibody-based therapeutics. The company expects FDA feedback on tovecimig data this quarter, anticipating a BLA filing later this year, and is advancing other bispecific antibody candidates like CTX-8371 and CTX-10726 through their respective clinical phases. With $180 million in cash and marketable securities, Compass Therapeutics projects its operations to be funded into 2028.
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com
This article announces that Compass Therapeutics, Inc. filed a Form 8K on August 6th. The filing is available through Investing.com, a financial markets platform. The news briefly mentions the company's stock symbol CMPX and its performance, but primarily serves as a notification about the SEC filing.
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its price momentum, support and resistance levels, and various technical indicators. The stock currently has a price momentum score of 4.33, trading between resistance at $2.28 and support at $1.77. While some indicators suggest a 'Sell' signal, the overall signal based on moving averages and other technical indicators is 'Neutral'.
CMPX|Compass Therapeutics Inc.|Price:1.940|
This article provides a detailed overview of Compass Therapeutics Inc. (CMPX), including its current market trends, real-time quotes, and related analysis. It highlights the company's healthy fundamentals, significant growth potential, and "Buy" ratings from analysts, despite recent stock market underperformance. The company is a clinical-stage oncology-focused biopharmaceutical firm developing antibody-based therapeutics.
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022
This article provides a detailed company profile of Compass Therapeutics, Inc., a clinical-stage oncology biopharmaceutical company. It outlines their proprietary antibody-based therapeutic pipeline, including lead candidate tovecimig and other programs like CTX-471 and CTX-8371, which target various critical biological pathways for anti-tumor responses. The report also includes company information, key executive details, and institutional shareholding data.
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Compass Therapeutics Inc. (CMPX), although it states that relevant data for FY2024, FY2025, and its quarters have not yet been disclosed by the company. It briefly touches on regional revenue, noting an unstated amount for the United States, and also mentions business segments.
CMPX|Compass Therapeutics Inc.|Price:2.080|
This article provides a comprehensive stock analysis of Compass Therapeutics Inc. (CMPX), highlighting its healthy fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. It details the company's product pipeline including tovecimig, CTX-471, and CTX-8371, and notes high institutional ownership and a "Buy" rating from analysts with an average target price of $8.50. The analysis also covers various scoring dimensions including financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment, making it suitable for informed investment decisions.
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Compass Therapeutics Inc. (CMPX), assigning it a current financial score of 6.37, which ranks 259 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, but its operating efficiency is low. Key financial metrics related to Cash and cash equivalents, Total assets, Operating profit, Income after tax, and Free cash flow are mentioned, with a note that relevant data have not yet been disclosed by the company for these specific categories.
TradingKey
This article provides a detailed quarterly and annual income statement for Compass Therapeutics Inc. (CMPX). It includes financial data such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income, income before tax, income after tax, net income, and earnings per share. The piece also offers a FAQ section explaining how to read an income statement and defining key financial terms.
TradingKey
This article provides a detailed cash flow statement for Compass Therapeutics Inc. (CMPX), presenting quarterly and annual data for operating, investing, and financing activities. It also includes an FAQ section explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, with specific figures for CMPX. The data helps evaluate the company's financial health, illustrating how it generates and uses cash from its various business functions.
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX
This article provides a revenue breakdown for Compass Therapeutics, Inc. (NASDAQ: CMPX) on the TradingView platform. It highlights that the market was closed with no trades at the time of publication and offers financial data, news, community interaction, and technical analysis tools for the company.
Compass Therapeutics Inc. (CMPX) Institutional Confidence
Compass Therapeutics Inc. (CMPX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional investors hold 90.26% of outstanding shares, a 28.41% increase quarter-over-quarter. The largest institutional shareholder is Bill Nygren | OAKMX, although their holdings decreased by 77.39%.
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary
This article summarizes Compass Therapeutics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting key clinical results and upcoming regulatory milestones. Their lead asset, tovecimig, showed significant efficacy in biliary tract cancer, with an FDA meeting scheduled for early to mid-August and a rolling Biologics License Application submission planned for later this year. The company also provided updates on its pipeline, including a next-generation CD137 agonist and two bispecific antibodies, with multiple data readouts anticipated in the second half of the year.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that data for its drug, tovecimig, will be presented as an oral Proffered Paper at the European Society for Medical Oncology (ESMO) Congress in October 2026. The presentation will detail results from the randomized, controlled Phase 2/3 COMPANION-002 clinical trial, which evaluated tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. The abstract and presentation highlight the company's progress in developing proprietary antibody-based therapeutics for oncology.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its Tovecimig data, specifically from the randomized clinical trial COMPANION-002, has been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail results from its Phase 2/3 trial assessing tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. The presentation is scheduled for October 24, 2026, during the congress in Madrid, Spain.
Compass Therapeutics to present Phase 2/3 tovecimig trial results at ESMO 2026 in advanced biliary tract cancer
Compass Therapeutics will present Phase 2/3 clinical trial results for its bispecific antibody, tovecimig, combined with paclitaxel, at the ESMO Congress 2026. The presentation will focus on data from the COMPANION-002 trial in advanced biliary tract cancer, led by Dr. Nilofer Azad. This event is expected to highlight Compass's oncology pipeline and advance treatment options for this challenging cancer.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its abstract featuring data from the COMPANION-002 clinical trial of tovecimig, a bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail results of the randomized Phase 2/3 trial evaluating tovecimig in combination with paclitaxel for previously treated patients with advanced biliary tract cancer. The congress will be held in Madrid, Spain, from October 23-27, 2026, with the presentation scheduled for October 24.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics will present data on its drug candidate, tovecimig, at the ESMO Congress in October 2026. The oral presentation will detail results from the Phase 2/3 COMPANION-002 clinical trial, which evaluated tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. Dr. Nilofer Azad will deliver the presentation.
Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Compass Therapeutics presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting progress on four clinical-stage oncology drugs. The lead asset, tovecimig, is advancing toward potential FDA BLA filing and showed significant efficacy in a phase II/III BTC trial. The company reported $195 million in cash at the end of Q1 2026, providing runway into 2028, with regulatory and commercial plans underway for tovecimig.
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update
Compass Therapeutics (CMPX), a biotech company, is generating significant retail investor interest ahead of its Phase 2/3 trial data release for its cancer drug Tovecimig, used to treat advanced biliary tract cancer. The drug, in combination with Paclitaxel, has shown promising earlier results with a higher overall response rate compared to Paclitaxel alone. Despite an 11% pre-market dip, retail sentiment remains "extremely bullish" as investors anticipate progression-free survival and overall survival results.
If You Invested $1,000 in Compass Therapeutics Inc (CMPX)
This article analyzes the historical performance of investing $1,000 in Compass Therapeutics Inc (CMPX) over different periods, detailing the current worth of such an investment and its annual returns. It also provides a comprehensive overview of Compass Therapeutics, a clinical-stage oncology biopharmaceutical company, highlighting its scientific focus on antibody-based therapeutics, key product candidates like Tovecimig and CTX-8371, and its development in various oncology indications. The article emphasizes the company's strategy of targeting angiogenesis, immune regulation, and tumor growth through its proprietary pipeline.
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)
Citizens has reiterated a Market Outperform rating on Compass Therapeutics (CMPX) with a $10 price target after the company presented promising clinical data at the ASCO conference for its bispecific antibody, CTX-8371. This drug showed early signs of activity in treating difficult cancers. Upcoming catalysts for CMPX include an FDA meeting in August for Tovecimig and new data releases for CTX-8371 and CTX-10726 later in 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from an April 27, 2026 announcement regarding a phase 2/3 study for its drug tovecimig, which, despite meeting a key secondary endpoint, missed another crucial one, overall survival, leading to a 64.41% stock price decline. Investors are encouraged to contact the firm for more information regarding this investigation.
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement
Compass Therapeutics (`CMPX`) has updated its corporate presentation, revealing positive Phase 2/3 COMPANION-002 data for tovecimig in second-line biliary tract cancer (BTC). The data shows improved objective response rate (ORR) and progression-free survival (PFS) for a combination therapy. The company plans to engage with the FDA in Q3 2026 for a Biologics License Application (BLA) submission in late 2026.
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success
Compass Therapeutics' tovecimig, in combination with paclitaxel, showed significant improvement in overall response rate (18.0% vs. 5.3%) and progression-free survival (4.7 months vs. 2.6 months) in a Phase 2/3 trial for second-line biliary tract cancer. The company plans an FDA meeting in Q3 2026 and a Biologics License Application (BLA) filing in Q4 2026, targeting potential approval in 2027 for a U.S. market estimated at over $3 billion. Compass also detailed its broader oncology pipeline and reported $195 million in cash, providing runway into 2028.
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which met a key secondary endpoint but missed another crucial one related to overall survival. The law firm is encouraging investors who purchased Compass securities to inquire about a potential securities investigation.
Price to earnings forward of Compass Therapeutics, Inc. – NASDAQ:CMPX
This article focuses on the "Price to earnings forward" financial metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). While the article title presents this topic, there is no actual data or discussion provided within the content. The body of the article appears to be primarily composed of navigation links, copyright information, and general site features rather than specific financial analysis.
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX
This page displays the "Price to sales forward" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX) as provided by TradingView. The content primarily focuses on financial data for the company within the Pharmaceuticals: Major sector and indicates market closure with no current trades.
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX
This article focuses on the "Enterprise value to revenue forward" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). The content is primarily a header with navigation and footer details, indicating a financial data point for the company on the TradingView platform.
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark
Compass Therapeutics, Inc. (NasdaqCM:CMPX), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has been dropped from the Russell 3000E Growth Benchmark. The company's stock shows a 5-day change of +0.48% and a year-to-date change of -61.27%. Compass Therapeutics is developing antibody-based therapeutics, with lead candidates like tovecimig and CTX-471 targeting various pathways for anti-tumor responses.
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark
Compass Therapeutics, Inc. (NasdaqCM:CMPX) has been removed from several Russell benchmarks, including the Russell Small Cap Comp Growth Benchmark, Russell 3000 Growth Benchmark, and Russell Microcap Growth Benchmark Index. This news follows a recent downgrade by Raymond James and a lowered price target by Wedbush after the company's Tovecimig study failed to meet its overall survival endpoint in biliary tract cancer, causing its shares to fall. The company is a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics.
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX)
This article provides an overview of Compass Therapeutics, Inc. (NASDAQ:CMPX) stock data, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, discusses upcoming earnings reports, and provides answers to frequently asked questions about investing in CMPX.
CMPX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Compass Therapeutics, Inc. (CMPX) stock for 2027 based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, and key financial information like recent earnings, revenue, and employee count. The article also addresses frequently asked questions regarding purchasing CMPX stock and its investment outlook.
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Compass Therapeutics Inc. (CMPX), highlighting its current valuation score, market capitalization, and P/E ratio. As of June 26, 2026, the company's valuation score is 8.69, ranking 104 out of 387 in the Biotechnology & Medical Research industry. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for Compass Therapeutics (CMPX). It serves as a resource for investors looking for insights into the company's financial prospects and market sentiment.
